{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:34:33Z","timestamp":1760099673076},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[1995,11,1]],"date-time":"1995-11-01T00:00:00Z","timestamp":815184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[1995,11]]},"DOI":"10.1007\/bf01526559","type":"journal-article","created":{"date-parts":[[2005,4,29]],"date-time":"2005-04-29T22:31:09Z","timestamp":1114813869000},"page":"389-396","source":"Crossref","is-referenced-by-count":14,"title":["Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K"],"prefix":"10.1007","volume":"41","author":[{"given":"E.","family":"Yefenof","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Gafanovitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Oron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0305-7372(84)90005-7","volume":"11","author":"S Tsukagoshi","year":"1984","unstructured":"Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita K (1984) Krestin (PSK). Cancer Treat Rev 11: 131","journal-title":"Cancer Treat Rev"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1128\/JVI.51.1.117-122.1984","volume":"51","author":"K Ebihara","year":"1984","unstructured":"Ebihara K, Minamishima Y (1984) Protective effect of biological response modifiers on murine cytomegalovirus infection. J Virol 51: 117","journal-title":"J Virol"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0192-0561(83)90069-3","volume":"5","author":"MJ Enrke","year":"1983","unstructured":"Enrke MJ, Reino JM, Eppolito C, Mihich E (1983) The effect of PSK, a protein bound polysaccharide on immune responses against allogeneic antigens. Int J Immunopharmacol 5: 35","journal-title":"Int J Immunopharmacol"},{"key":"CR4","first-page":"61","volume":"76","author":"M Hosokawa","year":"1985","unstructured":"Hosokawa M, Mizukoshi T, Sugawara M, Kobayashi H (1985) Therapeutic effects of PSK and busulfan on the recurrent and metastatic diseases after the surgical removal of 3-methylcholanthrene-induced autochtonous tumors in C57BL\/6 mice. Gann 76: 61","journal-title":"Gann"},{"key":"CR5","first-page":"699","volume":"69","author":"M Kondo","year":"1978","unstructured":"Kondo M, Kato H, Yokoe N, Matsumura N, Hotta T, Masasuke M (1978) Activation of the complement by immunostimulants, BCG, OK-432 (Picibani), and PS-K (Krestin) in vitro. Gann 69: 699","journal-title":"Gann"},{"key":"CR6","first-page":"5176","volume":"42","author":"Y Mizushima","year":"1982","unstructured":"Mizushima Y, Yuhki N, Hosokawa M, Kobayashi H (1982) Diminution of cyclophosphamide-induced suppression of antitumor immunity by an immunomodulator PSK and combined therapeutic effects of PSK and cyclophosphamide on transplanted tumor in rats. Cancer Res 42: 5176","journal-title":"Cancer Res"},{"key":"CR7","first-page":"365","volume":"66","author":"K Nomoto","year":"1975","unstructured":"Nomoto K, Yoshikumi C, Matsunaga K, Fujii T, Takeya K (1975) Restoration of antibody-forming capacities by PS-K in tumorbearing mice. Gann 66: 365","journal-title":"Gann"},{"key":"CR8","first-page":"215","volume":"4","author":"S Tsurku","year":"1983","unstructured":"Tsurku S, Nomoto K (1983) Effects of PSK on specific tumor immunity to syngeneic tumor cells. J Clin Lab Immunol 4: 215","journal-title":"J Clin Lab Immunol"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF01740932","volume":"31","author":"M Torisu","year":"1990","unstructured":"Torisu M, Hayashi Y, Ishimitsu T, Fujimura T, Iwasaki K, Katano M, Yamamoto H, Kimura Y, Takesue M, Motoharu K, Nomoto K (1990) Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother 31: 261","journal-title":"Cancer Immunol Immunother"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/S0140-6736(94)90233-X","volume":"343","author":"H Nakazato","year":"1994","unstructured":"Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J (1994) Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 343: 1122","journal-title":"Lancet"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF02050666","volume":"35","author":"T Mitomi","year":"1992","unstructured":"Mitomi T (1992) Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. Dis Colon Rectum 35: 123","journal-title":"Dis Colon Rectum"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1177\/030006058801600406","volume":"16","author":"T Fujii","year":"1988","unstructured":"Fujii T, Saito K, Oguchi Y, Matsunaga K, Kobayashi Y, Yoshikumi C, Taguchi T (1988) Effects of the protein-bound polysacharide preparation, PSK on spontaneous breast cancer in mice. J Int Med Res 16: 286","journal-title":"J Int Med Res"},{"key":"CR13","first-page":"307","volume":"98","author":"T Yamane","year":"1989","unstructured":"Yamane T, Fujita Y, Sagara Y, Okuzumi J, Kuwata K, Tanaka M, Takahashi T (1989) The effect of a protein-bound polysaccharide preparation, PS-K, on carcinogenesis in the glandular stomach of rats induced byN-methyl-N'-nitro-N-nitrosoguanidine. J Kyoto Prefect Univ Med 98: 307","journal-title":"J Kyoto Prefect Univ Med"},{"key":"CR14","first-page":"385","volume":"12","author":"T Nakajima","year":"1990","unstructured":"Nakajima T, Ichikawa S, Uchida S, Komada T (1990) Effects of a protein-bound polysaccharide from a basidiomycetes against hepatocarcinogenesis induced by \u20323-methyl-4-dimethylaminoazobenzene in rats. Clin Ther 12: 385","journal-title":"Clin Ther"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1126\/science.1957166","volume":"254","author":"BE Henderson","year":"1991","unstructured":"Henderson BE, Ross RK, Pike MC (1991) Towards the primary prevention of cancer. Science 254: 1131","journal-title":"Science"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/bjc.1991.276","volume":"66","author":"M Baum","year":"1991","unstructured":"Baum M, Ziv Y, Colletta AA (1991) Can we prevent breast cancer? Br J Cancer 66: 205","journal-title":"Br J Cancer"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/315190a0","volume":"315","author":"G Klein","year":"1985","unstructured":"Klein G, Klein E (1985) Evolution of tumors and the impact of molecular oncology. Nature 315: 190","journal-title":"Nature"},{"key":"CR18","first-page":"3713","volume":"49","author":"RA Weinberg","year":"1989","unstructured":"Weinberg RA (1989) Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 49: 3713","journal-title":"Cancer Res"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0168-9525(93)90209-Z","volume":"9","author":"B Vogelstein","year":"1993","unstructured":"Vogelstein B, Kinzler KW (1993) The multistep nature of cancer. Trends Genet 9: 138","journal-title":"Trends Genet"},{"key":"CR20","first-page":"217","volume-title":"Tumor suppressor genes","author":"LA Wakefield","year":"1990","unstructured":"Wakefield LA, Sporn MB (1990) Suppression of carcinogenesis: a role for TGF-\u03b2 and related molecules in prevention of cancer. In: Klein G (ed) Tumor suppressor genes. Dekker, New York, p 217"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/jnci\/60.3.707","volume":"60","author":"N Haran-Ghera","year":"1978","unstructured":"Haran-Ghera N (1978) Spontaneous and induced preleukemia cells in C57BL\/6 mice. J Natl Cancer Inst 60: 707","journal-title":"J Natl Cancer Inst"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0065-230X(08)60894-5","volume":"30","author":"N Haran-Ghera","year":"1979","unstructured":"Haran-Ghera N, Peled A (1979) Induction of leukemia in mice by irradiation and radiation leukemia virus variants. Adv Cancer Res 30: 45","journal-title":"Adv Cancer Res"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ijc.2910390415","volume":"39","author":"Y Ben-David","year":"1987","unstructured":"Ben-David Y, Kotler M, Yefenof E (1987) Leukemogenic, immunogenic and genetic properties of a thymotropic radiation leukemia virus. Int J Cancer 39: 492","journal-title":"Int J Cancer"},{"key":"CR24","first-page":"6590","volume":"47","author":"Y Ben-David","year":"1987","unstructured":"Ben-David Y, Yefenof E, Kotler M (1987) Clonal analysis of radiation leukemia virus (RadLV) induced leukemic and preleukemic cells. Cancer Res 47: 6590","journal-title":"Cancer Res"},{"key":"CR25","first-page":"2179","volume":"51","author":"E Yefenof","year":"1991","unstructured":"Yefenof E, Epsztein S, Kotler M (1991) Quantitation, in vitro propagation and characterization of preleukemic cells induced by radiation leukemia virus. Cancer Res 51: 2179","journal-title":"Cancer Res"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ijc.2910500325","volume":"50","author":"E Yefenof","year":"1992","unstructured":"Yefenof E, Ela C, Kotler M, Vitetta ES (1992) Induction of IL-4 secretion by the radiation leukemia virus (RadLV): role in autocrine growth stimulation of RadLV infected pre-leukemic cells. Int J Cancer 50: 481","journal-title":"Int J Cancer"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1073\/pnas.89.2.728","volume":"89","author":"E Yefenof","year":"1992","unstructured":"Yefenof E, Abboud G, Epsztein S, Vitetta ES (1992) Treatment of premalignancy: prevention of lymphoma in radiation leukemia virus inoculated mice by cyclosporin A and immunotoxin. Proc Natl Acad Sci USA 89: 728","journal-title":"Proc Natl Acad Sci USA"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0092-8674(74)90065-8","volume":"1","author":"M Haas","year":"1974","unstructured":"Haas M (1974) Continuous production of radiation leukemia virus in C57BL thymona tissue culture lines: purification of the leukemogenic virus. Cell 1: 79","journal-title":"Cell"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"600","DOI":"10.4049\/jimmunol.118.2.600","volume":"118","author":"N Haran-Ghera","year":"1977","unstructured":"Haran-Ghera N, Ben-Yaakov M, Peled A (1977) Immunologic characteristics in relation to high and low leukemogenic activity of radiation leukemia virus variants. J Immunol 118: 600","journal-title":"J Immunol"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1084\/jem.152.6.1473","volume":"152","author":"E Yefenof","year":"1980","unstructured":"Yefenof E, Meidav A, Kedar E (1980) In vitro generation of cytotoxic lymphocytes against radiation and radiation leukemia virus (RadLV) induced tumors: III. Suppression of anti-tumor immunity in vitro by lymphocytes of mice undergoing RadLV induced leukemogenesis. J Exp Med 152: 1473","journal-title":"J Exp Med"},{"key":"CR31","first-page":"2626","volume":"48","author":"RJ Fulton","year":"1988","unstructured":"Fulton RJ, Uhr JW, Vitetta ES (1988) In vitro therapy of the BCL1 tumor: Effect of immunotoxin valency and deglycosylation of the ricin A chain. Cancer Res 48: 2626","journal-title":"Cancer Res"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/335796a0","volume":"335","author":"AM Pullen","year":"1988","unstructured":"Pullen AM, Marrack P, Kappler JW (1988) The T cell repertoire is heavily influenced by tolerance to polymorphic self antigens. Nature 335: 796","journal-title":"Nature"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF02115007","volume":"31","author":"K Tomonari","year":"1990","unstructured":"Tomonari K, Lovering E, Spencer S (1990) Correlation between the V\u03b24+CD8+ T cell population and the H-2d haplotype. Immunogenetics 31: 333","journal-title":"Immunogenetics"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/332040a0","volume":"332","author":"HR MacDonald","year":"1988","unstructured":"MacDonald HR, Schneider R, Less RK, Howe RC, Acha-Orbea H, Festenstein H, Zinkernagel RM, Hengartner H (1988) T-cell receptor V\u03b2 use predicts reactivity and tolerance to Mlsa-encoded antigens. Nature 332: 40","journal-title":"Nature"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.4049\/jimmunol.134.6.3994","volume":"134","author":"U Staerz","year":"1985","unstructured":"Staerz U, Rammensee H, Benedetto J, Bevan M (1985) Characterization of a murine monoclonal antibody specific for an allotypic determinant on T cell antigen receptor. J Immunol 134: 3994","journal-title":"J Immunol"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1084\/jem.160.2.452","volume":"160","author":"K Haskins","year":"1984","unstructured":"Haskins K, Hannum C, White J, Roehm N, Kubo R, Kappler J, Marrack P (1984) The antigen specific, major histocompatibility complex-restricted receptor on T cells. VI. An antibody to a receptor allotype. J Exp Med 160: 452","journal-title":"J Exp Med"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/332035a0","volume":"332","author":"JW Kappler","year":"1988","unstructured":"Kappler JW, Staerz U, White J, Marrack PC (1988) Self-tolerance eliminates T cells specific for M1s-modified products of the major histocompatibility complex. Nature 332: 35","journal-title":"Nature"},{"key":"CR38","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF00355377","volume":"28","author":"K Tomonari","year":"1988","unstructured":"Tomonari K, Lovering E (1988) T cell receptor specific monoclonal antibodies against a V\u03b211 positive mouse T cell clones. Immunogenetics 28: 445","journal-title":"Immunogenetics"},{"key":"CR39","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0092-8674(87)90567-8","volume":"49","author":"JW Kappler","year":"1987","unstructured":"Kappler JW, Wade T, White J, Kushner E, Blackman M, Bill J, Roehm N, Marrack P (1987) A T cell receptor V\u03b2 segment that imparts reactivity to a class II major histocompatibility complex product. Cell 49: 263","journal-title":"Cell"},{"key":"CR40","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/284555a0","volume":"284","author":"AH Wyllie","year":"1980","unstructured":"Wyllie AH (1980) Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284: 555","journal-title":"Nature"},{"key":"CR41","unstructured":"Reference deleted"},{"key":"CR42","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0952-7915(06)80028-2","volume":"4","author":"B Fleischer","year":"1992","unstructured":"Fleischer B (1992) Superantigens. Curr Opin Immunol 4: 392","journal-title":"Curr Opin Immunol"},{"key":"CR43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF01741348","volume":"34","author":"E Yefenof","year":"1991","unstructured":"Yefenof E, Einat E, Klein E (1991) Potentiation of T cell immunity against radiation-leukemia-virus-induced lymphoma by polysaccharide K. Cancer Immunol Immunother 34: 133","journal-title":"Cancer Immunol Immunother"},{"key":"CR44","first-page":"5795","volume":"50","author":"G Boccoli","year":"1990","unstructured":"Boccoli G, Masciulli R, Ruggeri EM, Carlini P, Giannella G, Mongtesoro E, Mastroberardino G, Isacchi G, Testa U, Calabresi F, Peschle C (1990) Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose Interleukin 2 Bolus treatment. Cancer Res 50: 5795","journal-title":"Cancer Res"},{"key":"CR45","first-page":"140","volume":"9","author":"S Dupere","year":"1990","unstructured":"Dupere S, Obiri N, Lackey A, Emma D, Yannelli J, Orr D, Birch R, O'Conner TE (1990) Patterns of cytokines released by peripheral blood leukocytes of normal donors and cancer patients during interleukin-2 activation in vitro. J Biol Responses Mod 9: 140","journal-title":"J Biol Responses Mod"},{"key":"CR46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF01741324","volume":"34","author":"JS Economou","year":"1991","unstructured":"Economou JS, Hoban M, Lee JD, Essner R, Swisher S, McBride W, Hoon DB, Morton DL (1991) Production of tumor necrosis factor \u03b1 and interferon \u03b3 in interleukin-2-treated melanoma patients: correlation with clinical toxicity. Cancer Immunol Immunother 34: 49","journal-title":"Cancer Immunol Immunother"},{"key":"CR47","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.1987.5.3.496","volume":"5","author":"JT Vetto","year":"1987","unstructured":"Vetto JT, Papa MZ, Lotze MT, Chang AE, Rosenberg SA (1987) Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. J Clin Oncol 5: 496","journal-title":"J Clin Oncol"},{"key":"CR48","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.1989.7.4.486","volume":"7","author":"KA Margolin","year":"1989","unstructured":"Margolin KA, Rayner AA, Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Doroshow JH, Jaffe HS, Roper M, Parkinson DR, Wiernik PH, Creekmore SP, Boldt DH (1989) Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 7: 486","journal-title":"J Clin Oncol"},{"key":"CR49","first-page":"538","volume":"9","author":"RM Bukowski","year":"1990","unstructured":"Bukowski RM, Murthy S, Sergi J, Budd GT, McKeever S, Medendorp SV, Tubbs R, Gibson V, Finke J (1990) Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-\u03b12a: Clinical effects. J Biol Response Mod 9: 538","journal-title":"J Biol Response Mod"}],"container-title":["Cancer Immunology Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01526559\/fulltext.html","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01526559.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01526559\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01526559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T03:35:09Z","timestamp":1683084909000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01526559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,11]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1995,11]]}},"alternative-id":["BF01526559"],"URL":"https:\/\/doi.org\/10.1007\/bf01526559","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,11]]}}}